Aethlon Medical Announces Conference Presentations and Research Coverage.

Business Editors/Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--March 12, 2004

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that its Chairman and CEO, Mr. James A. Joyce will be a featured presenter at the Investment Opportunities in Homeland Defense and Security Conference, to be held at the National Press Club in Washington D.C. on March 30, 2004. Archived streaming audio of the presentation will be available on the web at: www.domesticpreparedness.com. Additionally, Mr. Joyce is scheduled to present at the Growth Capital Conference XII to be held at The Olympic Collection in Los Angeles on April 1, 2004. Information available at: www.gcc2000.org

Aethlon Medical also announced that The Research Works, Inc. has published analysts' coverage on the Company. Aethlon Chairman and CEO, James A. Joyce stated: "We commissioned the creation of this report as a means to increase knowledge and awareness of our Company." Mr. Joyce continued: "We are certainly impressed with The Research Works professionalism, and more importantly, their proven history of discovering early stage emerging growth companies." The report is now available for review at: www.stocksontheweb.com/aemd.htm

About The Research Works

The Research Works is an equity research boutique founded in 1992 and focused on small-cap, microcap and penny stocks. The Research Works' stated objective is to discover undervalued small companies and help them achieve fair value for their stocks by producing high-quality research reports that are grounded in fundamental analysis and employ state-of-the-art equity valuation models. The Research Works targets a far-reaching network of sophisticated, self-directed investors and distributes its research through a strong Internet presence and a large direct-distribution list.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the Hemopurifier(TM) to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. For additional information, visit the company's Web site at www.AethlonMedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.